Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.
Ovejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Talegón M, Cabaleiro T, Daudén E, Abad-Santos F.
Ovejero-Benito MC, et al.
Pharmacogenomics. 2018 Jan;19(1):7-16. doi: 10.2217/pgs-2017-0143. Epub 2017 Dec 1.
Pharmacogenomics. 2018.
PMID: 29192552
Free article.